Quarterly Activity Report and Appendix C

Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in…

Proposed Issue of Securities — IBX

Imagion Biosystems Limited has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.

Proposed Issue of Securities — IBXOA

Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.

IBX Raises $5M in Oversubscribed Placement

$5M raised in an oversubscribed placement at 4.5c per share – equivalent to 30 day VWAP, and a 33.9% premium to 60 day VWAP. Strongly supported by existing…

Appendix 2A

The application for quotation (Appendix 2A) for listed options (IBCOA) was released to the market. Read Appendix 2A.

Trading Halt

The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement regarding a…

Results of the Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Imagion Biosystems Limited advises the results its 2019 Annual…

Chairman's Address to Shareholders at Annual General Meeting

Imagion Biosystems announces the transcript of the Chairman's address to shareholders at the Annual General Meeting. Read the transcript.

Research Shows Imagion Nanoparticles Enable Low-field MRI

Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron…

Imagion Biosystems Announces Transition of CFO Role

Imagion Biosystems Limited announces that its Chief Financial Officer, Brian Conn, will be leaving the Company effective 1st August 2020. Brian has served…